World Vaccines Market 2013-2023
Vaccines and their technology – your guide to developments, opportunities, and revenues
See what the future holds for vaccines. Visiongain's updated report lets you assess forecasted sales at overall world market, submarket, product, and national level to 2023.
Make sure you understand trends, R&D, opportunities, and prospects there, in human medicine, helping your research, analyses, and decisions. Discover in our work what's likely to happen for those technologies. You find there how you can benefit.
Read on to explore that industry and see what its future market could be worth.
Forecasts from 2013-2023 and other analyses show you commercial prospects
Besides revenue forecasting to 2023, our new study gives you historical data, recent results, growth rates, and market shares. There you find original analysis, with business outlooks and developments (R&D). You also get two interviews, 50 charts, and 91 tables.
Gains through understanding the vaccines sector – find advantages for your work
Leaders hold knowledge. So hear what's happening for development, production, and sales of those preventative medicines. There you see where needs and money exist, from 2013, finding how you and your organisation can prosper.
Use our predictions for vaccination, then, to help expand your business and give you more influence. Avoid falling behind there – try our new report.
So the following sections reveal what you get in that new investigation.
Revenues for the world vaccines market and submarkets
What're the secrets of that industry's progress? What's its potential? Discover in our report overall world revenue to 2023. Also find individual forecasts for four submarkets at world level:
• Paediatric products
• Influenza treatments
• Adult prophylactic agents
• Therapeutic vaccines.
How will sales rise? See, then, which product classes can generate most revenue. There you assess prospects for commercial expansion. Discover now the money-earning potential.
Explore the market for vaccinations by brand too.
Forecasts and discussions for leading products
How will leading brands perform to 2023 at world level? Our work shows you 10 individual revenue forecasts to 2023 for top products:
• Pentacel, Pediacel, and Pentaxim
• ProQuad, M-M-R II, and Varivax
• Fluzone, Panenza, Humenza, Intanza, IDflu, and Emerflu.
And also for these:
• Infanrix and Pediarix
• Engerix, Fendrix, Havrix, Twinrix, and Ambirix
• Menactra and other vaccines for meningitis and pneumonia
There you assess those agents, seeing activities, results and outlooks. You discover what's happening, understanding trends, competition, and sales prospects. Assess the future.
Our study also divides its overarching forecast into geographical regions.
Healthcare in national markets – what're the outlooks for vaccine sales?
Progress worldwide in medicine and healthcare will expand vaccination. You hear about the best revenue prospects for those preventative medicines, getting feel for national prospects.
Our analyses show you individual revenue forecasts to 2023 for 11 national markets:
• United States (US)
• Germany, France, UK, Italy, and Spain (EU5)
• Brazil, Russia, India, and China (BRIC).
There you assess developed and developing countries for revenues and potential sales growth. Our work explains. See effects of existing and future prophylactic medicines.
Research and development – explore trends, possibilities, and innovations
You also investigate R&D for immune system modifiers, finding possibilities for technological and commercial advances.
In particular, our report discusses these medical technologies:
• Paediatric agents – protecting infants and children
• Influenza vaccines for H5N1, H1N1, and H9N2
• Prophylactic treatments, including those for meningitis, pneumonia, TB, diphtheria, Pertussis, tetanus, and rotaviruses
• Protectors against dengue virus, anthrax, and other forms of bio-terrorism.
And these, too, among others:
• Vaccines for HIV, malaria, and bacteria
• Prophylaxis in oncology – prostate, lung, and melanoma
• Agents for renal, colorectal, and haematological cancers
• Products for breast, pancreatic, ovarian, and brain cancers.
Developments for those immunological treatments hold strength, variety, and promise. See what's possible there for large pharmaceutical companies and biopharma specialists.
The rise of H7N9 influenza in 2013 shows how pandemic flu creates needs. Also, the therapeutic vaccines segment has a strong R&D pipeline. It holds over 20 late-stage candidates for solid-tumour cancers and other chronic diseases. Find promising research.
Our study explains progress in human prophylaxis, discussing issues to help your work.
Events affecting developers, producers, and sellers of vaccines
The report explains forces affecting that industry and market from 2013, including these:
• Pro-immunisation stance in the US
• Medical needs vying with budgetary restraints in Europe
• Rising demand in emerging countries and under-developed regions.
And other aspects of the technology, such as these:
• Importance of those products to the pharmaceutical industry
• Opportunities in MRSA, HIV, and other applications
• Delivery systems, new adjuvants, 2D barcoding, and other innovations.
There you explore political, economic, social, and technological questions, investigating outlooks for business. Examine forces stimulating and restraining that industry and market. You discover what their present and future hold.
Companies and overall 2017 market value – what predicted revenue?
What happens next? Our report predicts the world market for vaccines will reach $48bn in 2017 – with high sales growth – and expand further to 2023.
Find how high its revenues can go. Discover in our work what's possible for prophylactic medicine, and see which companies hold greatest potential.
In particular, you explore these organisations:
• Sanofi Pasteur
• GlaxoSmithKline (GSK)
• Merck & Co.
From 2013 to 2023 vaccines will benefit patients, payers, and companies. Our analysis predicts technological and commercial advances there. Stay ahead by using that work.
Data found nowhere else – explore vaccine development, production, and sales
In particular, then, our new investigation gives you these advantages:
• Revenues to 2023 for vaccines at world level, 4 submarkets, and 10 products or their groups – assess prospects for investments, marketing, and sales
• Forecasts to 2023 for 11 national markets in the Americas, Europe, and Asia – investigate developed and developing countries for potential revenues
• Prospects for established competitors, rising companies, and new entrants – explore products, R&D, and outlooks for success.
World Vaccines Market 2013-2023 provides independent research and analysis. There you get competitive intelligence found only in our work, finding where the money lies. Explore progress and possibilities.
With that report you're less likely to miss knowledge and opportunity. Also find there how you could save time and gain more recognition for insight.
Ordering now lets you discover trends, predictions, and sales opportunities for vaccines
Our new report is for everyone analysing preventative medicines and related biotechnology. There you discover predictions and discussions. Avoid missing out – please order now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
To view free sample pages of this report please click here